Navigation Links
Genomic Health Announces Year-End 2011 Financial Results, Provides 2012 Financial Outlook
Date:2/6/2012

REDWOOD CITY, Calif., Feb. 6, 2012 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the year ended December 31, 2011.  

Total revenue for the year ended December 31, 2011 increased to $206.1 million, compared with $178.1 million in 2010, an increase of 16 percent.  Product revenue was $204.8 million, compared with $174.9 million in 2010, an increase of 17 percent.  Contract revenue comprised the balance of total revenue for each of these periods.  

Net income was $7.8 million for the year ended December 31, 2011, compared with $4.3 million in 2010. Basic and diluted net income per share applicable to common stockholders was $0.27 and $0.26, respectively in 2011, compared with $0.15 and $0.14 per share, respectively, in 2010.

Total revenue for the fourth quarter of 2011 increased to $53.4 million, compared with $47.1 million in the fourth quarter of 2010.  Product revenue was $53.2 million in the fourth quarter of 2011, compared with $46.3 million for the fourth quarter of 2010, an increase of 15 percent.  Net income in the fourth quarter of 2011 was $2.6 million, compared with $1.7 million in the fourth quarter of 2010.  Basic and diluted net income per share applicable to common stockholders was $0.09 and $0.08, respectively, for the fourth quarter of 2011, compared with $0.06 per share in the fourth quarter of 2010.

"In 2011, we increased our financial strength and generated $7.8 million in profit while making important progress across our commercial and pipeline programs," said Kim Popovits, President and Chief Executive Officer of Genomic Health.  "As we look ahead, we remain focused on providing solutions that deliver better outcomes for cancer patients worldwide by continuing to expand our Oncotype DX® services to include pros
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Genomic Health Presents Results From First Clinical Decision Making Study of Oncotype DX® Colon Cancer at the 2012 Gastrointestinal Cancers Symposium
2. Synthetic Genomics Inc. Hires Industry Leader George E. Stagnitti to Head Food and Nutritional Products Development Program
3. QIAGEN Gains Rights to Genomic Biomarkers for Lung, Brain and Other Cancers to Expand its Pipeline of Companion Diagnostics
4. Genomic Technologies: Market Insights for Life Science Suppliers
5. SwitchGear Genomics and New England Biolabs Develop New Multiplex Reporter Assay System
6. Synthetic Genomics Inc. and Plenus, S.A. de C.V. Form New Sustainable Agriculture Company, Agradis, Inc. to Develop and Commercialize Products Using Genomic Technologies
7. New England Biolabs and Rubicon Genomics Enter into Distribution Agreement for Single Cell Amplification Products
8. Center for Proteomics at the Translational Genomics Research Institute (TGen) Selected as Waters Center of Innovation
9. Transgenomic Reports Second Quarter Financial Results
10. ACMG Announces New Online Live Learning Center: Will Bring Genetics and Genomics Education to Varied Health Professionals
11. Quest Diagnostics and Genomic Vision Form Strategic Collaboration to Develop Genome-based Laboratory Tests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2012)... 2012  Intellect Neurosciences, Inc. (OTCPK: ILNS) announces ... and CEO, will be presenting at the Seventh ... (Logo:  http://photos.prnewswire.com/prnh/20111214/NY22484LOGO ) The ... Neoepitopes Offer Attractive Targets for Active and Passive ... 21st at the Intercontinental Hotel in Boston from ...
(Date:5/16/2012)... LOUIS, May 16, 2012  Sigma-Aldrich announced today ... revolving credit facility that will mature on May ... million revolving credit facility that was scheduled to ... facility will provide back-up liquidity for the commercial ... purposes. Wells Fargo Securities LLC, Merrill ...
(Date:5/16/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... http://www.reportlinker.com/p090668/Global-Biotechnology-Instrumentation-Industry.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=In_Vitro_ This ... Biotechnology Instrumentation in US$ Million by ... Protein/Peptide Synthesizers, DNA Sequencers, Protein/Peptide Sequencers, ...
(Date:5/15/2012)... taken a step toward overcoming a key ... could bring optical advances including ultrapowerful microscopes, ... have shown how to create the metamaterials ... required, said Alexandra Boltasseva, a Purdue University ... , Using the metals is impractical for ...
Breaking Biology Technology:Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 2Intellect Neurosciences, Inc. to Present at Neurotech Investing and Partnering Conference 3Global Biotechnology Instrumentation Industry 2Global Biotechnology Instrumentation Industry 3Global Biotechnology Instrumentation Industry 4Global Biotechnology Instrumentation Industry 5Global Biotechnology Instrumentation Industry 6Global Biotechnology Instrumentation Industry 7Global Biotechnology Instrumentation Industry 8Global Biotechnology Instrumentation Industry 9Global Biotechnology Instrumentation Industry 10Global Biotechnology Instrumentation Industry 11Global Biotechnology Instrumentation Industry 12Global Biotechnology Instrumentation Industry 13Global Biotechnology Instrumentation Industry 14Global Biotechnology Instrumentation Industry 15Global Biotechnology Instrumentation Industry 16Global Biotechnology Instrumentation Industry 17Global Biotechnology Instrumentation Industry 18Global Biotechnology Instrumentation Industry 19Global Biotechnology Instrumentation Industry 20New 'metamaterial' practical for optical advances 2New 'metamaterial' practical for optical advances 3
... Feb. 23 GeneraMedix, Inc. announced,today that it ... its improved,formulation of epoprostenol sodium for the intravenous ... a biopharmaceutical company with,its headquarters in Allschwil/Basel, Switzerland. ... "This sale speaks directly ...
... a developer of a pharmacogenomic test to identify potential ... Lilly and Company under the trademark Xigris (R)), announced ... at the annual Invest Northwest Investor-CEO forum conference on ... is presented by the Washington Biotechnology & Biomedical Association ...
... NEW YORK, Feb. 23 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, Inc. ... plans to release,fourth quarter and full year 2008 financial ... , The Company will hold ... 9, 2009 to,discuss fiscal fourth quarter and full year ...
Other Biology Technology:GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 2GeneraMedix, Inc. Announces Sale of Innovative Epoprostenol Formulation to Actelion Ltd. 3Sirius Genomics to Present at Invest Northwest Conference 2
(Date:5/20/2012)... May 2012. The Stem Cells and Cancer Research ... the Vall d,Hebrn Institute of Oncology (VHIO) has ... to certain drugs used in clinical trials for ... also benefited from the collaboration with Professor Alberto ... Alberto Sols, Consejo Superior de Investigaciones Cientficas (IIB-CSIC-Madrid). ...
(Date:5/18/2012)... /PRNewswire-iReach/ -- With chronic diseases continuing to ... and research to find "cures" continuing to take ... "a few years away," a small but growing ... the human consciousness. A number of healing practices ... geometry, and intention, have emerged, embracing practices first ...
(Date:5/18/2012)... McCauley and Paul DeSalles did not set out to ... documented. But that,s exactly what they and a team ... and faculty did in a new study published ... light on how human disturbance of the natural world ... ecological interaction chains. This, in turn, highlights the need ...
Breaking Biology News(10 mins):Discovery of mechanisms predicting response to new treatments in colon cancer 2Discovery of mechanisms predicting response to new treatments in colon cancer 3Healing Method from Australia Addresses the Human Genome 2Stanford scientists document fragile land-sea ecological chain 2Vivakor Confirms Record Date of Stock Dividend 15068 1Vivakor Confirms Record Date of Stock Dividend 15068 2Vivakor Confirms Record Date of Stock Dividend 15068 3Amber Pharmacy Earns Accreditation From ACHC 6764 1Amber Pharmacy Earns Accreditation From ACHC 6764 2Cholesterol lowering drugs also may protect stem cell transplant patients from GVHD 62638 1Cholesterol lowering drugs also may protect stem cell transplant patients from GVHD 62638 2
... researchers led by the Smithsonian Institution has completed a ... the hobbit, a 3-foot-tall, 18,000-year-old hominin skeleton, discovered four ... study offers one of the most striking confirmations of ... remnant of one of the oldest human migrations to ...
... recently discovered that a chemical chain reaction that controls ... could mean the difference between normal growth and cancer. ... Cell, describes how organs can grow uncontrollably huge and ... , This chain reaction, a domino-like chain of events ...
... HONOLULU, Sept. 20 Women with low levels of vitamin ... a study led by the University of Pittsburgh Graduate School ... meeting of the American Society for Bone and Mineral Research ... professor of epidemiology, and colleagues evaluated patient data on 400 ...
Other Biology News:New research sheds light on 'Hobbit' 2Controlling for size may also prevent cancer 2Low vitamin D linked to higher risk of hip fracture 2
Anti-Chicken IgY, (IgG) F(ab')2 Fragment Specific....
Presenilin 2 Immunogen: Synthetic peptide corresponding to residues 31-47 of human Presenilin 2. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Recognizes TWIK-2. Does not cross react with any other known proteins....
Sheep polyclonal to ErbB 2 ( Abpromise for all tested applications). Antigen: Recombinant full length c-ErbB2 protein (Human). Entrez GeneID: 2064 Swiss Protein ID: P04626...
Biology Products: